Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
Key claim: A preference-based study will compare hematopoietic stem cell transplantation (HCT) versus best available non-transplant therapies (BAT) in patients with high-risk myelofibrosis.
Abstract
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis. This will be done by asking participants to choose the treatment that they prefer to receive (HCT or BAT) and then comparing the outcomes of the participants in both treatment groups.
Why this matters
A preference-based study will compare hematopoietic stem cell transplantation (HCT) versus best available non-transplant therapies (BAT) in patients with high-risk myelofibrosis.